首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3338369篇
  免费   261320篇
  国内免费   7919篇
耳鼻咽喉   47025篇
儿科学   104954篇
妇产科学   89173篇
基础医学   476197篇
口腔科学   98070篇
临床医学   312454篇
内科学   645820篇
皮肤病学   67910篇
神经病学   280849篇
特种医学   128470篇
外国民族医学   1158篇
外科学   485922篇
综合类   77330篇
现状与发展   3篇
一般理论   1406篇
预防医学   282094篇
眼科学   77285篇
药学   248149篇
  10篇
中国医学   7032篇
肿瘤学   176297篇
  2019年   27533篇
  2018年   38497篇
  2017年   29336篇
  2016年   31656篇
  2015年   36187篇
  2014年   51083篇
  2013年   77595篇
  2012年   106606篇
  2011年   112713篇
  2010年   65414篇
  2009年   61266篇
  2008年   104172篇
  2007年   110745篇
  2006年   111008篇
  2005年   108157篇
  2004年   103700篇
  2003年   99346篇
  2002年   96061篇
  2001年   146562篇
  2000年   151223篇
  1999年   128100篇
  1998年   38054篇
  1997年   34441篇
  1996年   33809篇
  1995年   32606篇
  1994年   30661篇
  1993年   28739篇
  1992年   103211篇
  1991年   100275篇
  1990年   97078篇
  1989年   93158篇
  1988年   86547篇
  1987年   85095篇
  1986年   80918篇
  1985年   77330篇
  1984年   58786篇
  1983年   50150篇
  1982年   30545篇
  1981年   27181篇
  1979年   54736篇
  1978年   38708篇
  1977年   32380篇
  1976年   30823篇
  1975年   32336篇
  1974年   39706篇
  1973年   38209篇
  1972年   35583篇
  1971年   33014篇
  1970年   30912篇
  1969年   28644篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
71.
72.
73.
74.

Objective

Comparative survival between neoadjuvant chemotherapy and adjuvant chemotherapy for patients with cT2-4N0-1M0 non–small cell lung cancer has not been extensively studied.

Methods

Patients with cT2-4N0-1M0 non–small cell lung cancer who received platinum-based chemotherapy were retrospectively identified. Exclusion criteria included stage IV disease, induction radiotherapy, and targeted therapy. The primary end point was disease-free survival. Secondary end points were overall survival, chemotherapy tolerance, and ability of Response Evaluation Criteria In Solid Tumors response to predict survival. Survival was estimated using the Kaplan–Meier method, compared using the log-rank test and Cox proportional hazards models, and stratified using matched pairs after propensity score matching.

Results

In total, 330 patients met the inclusion criteria (n = 92/group after propensity-score matching; median follow-up, 42 months). Five-year disease-free survival was 49% (95% confidence interval, 39-61) for neoadjuvant chemotherapy versus 48% (95% confidence interval, 38-61) for adjuvant chemotherapy (P = .70). On multivariable analysis, disease-free survival was not associated with neoadjuvant chemotherapy or adjuvant chemotherapy (hazard ratio, 1.1; 95% confidence interval, 0.64-1.90; P = .737), nor was overall survival (hazard ratio, 1.21; 95% confidence interval, 0.63-2.30; P = .572). The neoadjuvant chemotherapy group was more likely to receive full doses and cycles of chemotherapy (P = .014/0.005) and had fewer grade 3 or greater toxicities (P = .001). Response Evaluation Criteria In Solid Tumors response to neoadjuvant chemotherapy was associated with disease-free survival (P = .035); 15% of patients receiving neoadjuvant chemotherapy (14/92) had a major pathologic response.

Conclusions

Timing of chemotherapy, before or after surgery, is not associated with an improvement in overall or disease-free survival among patients with cT2-4N0-1M0 non–small cell lung cancer who undergo complete surgical resection.  相似文献   
75.
76.
77.
78.
Depigmented lesions may occur as postinflammatory sequelae of subacute cutaneous lupus erythematosus (SCLE), leading to great psychosocial impact. A 53‐year‐old male patient presented with post‐SCLE depigmented facial lesions after five years of disease stability. We proposed surgical treatment with melanocyte‐keratinocyte transplantation procedure (MKTP), and after five months the patient achieved 90% repigmentation, without Koebner phenomenon (KP). In theory, KP is a possible complication of MKTP procedure since the preparation of the receptor area involves the use of dermabrasion. In an attempt to avoid it, we suggest to maintain the treatment of the underlying disease and wait for a minimum period of disease stability before the procedure.  相似文献   
79.
Chondrocytes are the main cells in the extracellular matrix (ECM) of articular cartilage and possess a highly differentiated phenotype that is the hallmark of the unique physiological functions of this specialised load-bearing connective tissue. The plasma membrane of articular chondrocytes contains a rich and diverse complement of membrane proteins, known as the membranome, which defines the cell surface phenotype of the cells. The membranome is a key target of pharmacological agents and is important for chondrocyte function. It includes channels, transporters, enzymes, receptors, and anchors for intracellular, cytoskeletal and ECM proteins and other macromolecular complexes. The chondrocyte channelome is a sub-compartment of the membranome and includes a complete set of ion channels and porins expressed in these cells. Many of these are multi-functional proteins with “moonlighting” roles, serving as channels, receptors and signalling components of larger molecular assemblies. The aim of this review is to summarise our current knowledge of the fundamental aspects of the chondrocyte channelome, discuss its relevance to cartilage biology and highlight its possible role in the pathogenesis of osteoarthritis (OA). Excessive and inappropriate mechanical loads, an inflammatory micro-environment, alternative splicing of channel components or accumulation of basic calcium phosphate crystals can result in an altered chondrocyte channelome impairing its function. Alterations in Ca2+ signalling may lead to defective synthesis of ECM macromolecules and aggravated catabolic responses in chondrocytes, which is an important and relatively unexplored aspect of the complex and poorly understood mechanism of OA development.  相似文献   
80.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号